Q2 2021 Colfax Corp Earnings Call
Thank you for standing by and welcome to the Colfax second quarters, you're talking into when you wanted to earnings call.
At this time all participants are in a listen only mode. After the speaker presentation, there will be a question and answer session.
Ask a question during the session you will need to press star 1 on your telephone.
Bad and they withdraw your question Breasty Hashed E. A gearbox any technical support please press star Zero I would now like to hand, the conference over to your free Speaker today, Mike Music. Please go ahead.
Thank you.
Morning, everyone and thank you for joining us I'm, Mike Mason, Vice President of Finance.
Joining me today on the call are Metro President and CEO Brady, Shirley Executive Vice President and CEO of Dji, and Chris Hix Executive Vice President and CFO.
Our earnings release was issued yesterday afternoon and is available in the Investor section of our website at Colfax Corp Dot com.
Using.
A slide presentation to walk through today's call, which can also be found on our website. Both the audio and slide presentation of this call will be archived on the website later today and will be available until our next quarterly earnings call.
During this call, we'll be making some forward looking statements about our beliefs and estimates regarding future events.
Results. These forward looking statements are subject to risks and uncertainties, including those set forth in the safe Harbor language in yesterday's earnings release and in our filings with the SEC.
Actual results might differ materially from any forward looking statements that we make today are forward looking statements speak only as of today and we do not.
Not assume any obligation or intend to update them, except as required by law.
With respect to any non-GAAP financial measures made during the call today. The accompanying reconciliation reconciliation information related to those measures can be found in our press release.
And today's slide presentation with that let me turn it over to Matt who will start.
Inventory.
Thanks, Mike welcome everyone and thanks for joining our call today I am pleased to report another strong quarter of financial results and strategic progress at Colfax.
We exceeded our second quarter expectations, both on the top line and earnings effectively managing through an improving but still dynamic operating.
On slide 9.
As a result, we're increasing our full year financial outlook.
We're also pleased to announce another exciting med Tech acquisition net further expands our fast growing reconstructive platform.
<unk> has joined today's call to provide more details about this strategic addition to our med Tech business.
And we also made strong progress towards separating our company into 2 independent public companies and continue to target completion in the first quarter of next year.
Our strong performance this quarter highlights the momentum and growth opportunities, we see in both med Tech and Aesop.
End markets continue to recover and both.
Businesses reported organic daily growth above 2020, and 2019 levels, including <unk>.
10% growth over 2019 in our med Tech reconstructive platform.
Despite some supply chain friction our global teams are executing well and continuing to outgrow.
Markets.
We expect continued market improvement in the second half of the year with accelerating growth over 2019.
Second quarter higher sales translated into higher profit and we earned adjusted EPS of <unk> 56 per share in the second quarter, a 27% sequential increase versus.
Growth in Milan, and above our guidance range of 48 to 53.
<unk> achieved EBITDA margins of 16, 4% another record while successfully managing high levels of raw material inflation.
We also posted another strong quarter of free cash flow and are well on our.
<unk> <unk> exceeding our original guidance of $250 million or more this year.
All of these improvements are reading through to our full year performance and we are increasing our 2021 guidance Chris will walk through these details later.
Slide 4 provides an update of our plans to separate.
Right into 2 independent public companies in the first quarter of next year.
Our experienced leaders are making substantial progress across many work streams and we remain on schedule.
We are complementing <unk> strong operating team with additional public company support capabilities shaman. His team have already hired several of these key.
Leaders and are well on their way to building a highly effective team of top talent.
We expect that the initial capital structure of SaaS will have net leverage of 2.5 to 3 times upon separation a very comfortable level given the business is strong and consistent cash flows and disciplined.
<unk> operations, we expect the business to have ample financial capacity to execute the growth strategy that we outlined at Investor day in March.
We selected a new name for Med Tech co that reflects our vision of continuous improvement innovation and great patient outcomes.
We have a thought.
Thoughtful and impactful plan to unveil the new named to investors customers and employees later in the year stay tuned.
The company has made significant progress, creating the 2 separate boards of directors.
Both businesses will benefit from a combination of continuity from existing directors and new members.
And on experiences and perspectives.
You will hear more from us on this important topic as we get closer to the separation.
We continue to target the separation to be completed in the first quarter of 2022, and we're confident that we will position both companies for maximum long term growth and value creation.
With this each of the businesses have demonstrated that they are ready for the separation by continuing to achieve strong operating performance and strategic progress.
Slide 5 demonstrates this in part through our record of sustainable margin improvement at <unk>.
Congratulations to the <unk> team for achieving another record.
In the quarter.
The improvement of almost 500 basis points since 2015 reflects the consistent execution of our profitable growth strategy and application of our proven business system across a range of conditions.
<unk> global teams use CBS tools.
This and processes every day to improve productivity across the regions factories and functions.
This continuous improvement is complemented by supply chain and back office consolidations that create structurally lower cost.
CBS has been used for growth successfully.
Tools and the teams on attractive commercial opportunities and <unk> market, leading innovation engine is also contributed to growth share gains and operating leverage.
Acquisitions have further positioned the business in attractive growth markets like medical and life science that reduced the cyclical exposure of the overall business.
Folks we are proud of this margin performance and the business is on track for even higher margins in the coming years as communicated at Investor Day.
At Investor Day, we also discussed the many acquisition vectors within our Med Tech business and slide 6 shows the significant progress made in the past few quarters to expand.
Spanned our market accelerate the growth and create a path to structurally higher margins.
We complemented our recovery sciences franchise with a fast growing laser technology that also opens opportunities in the vet space.
We made an important investment and insight.
Medical systems that could lead to a breakthrough augmented reality guidance technology for the surgical theater.
We created a fast growing foot and ankle franchise that we expect will reach $100 million of revenue within 3 years.
And now we're pleased to announce the acquisition of masses are highly complementary.
Terry Global expansion of our fast growing reconstructive platform.
When we established our med tech business with the acquisition of D. J O. We had revenue of about $1.2 billion.
And based on recon double digit organic growth and these acquisitions are med Tech segment.
<unk> now has over $1.5 billion of pro forma revenue. It is quickly tilting to faster growth.
We are well on our way to achieving the near term $2 billion revenue target discussed at Investor Day.
Slide 7 includes more information on matters.
Like T J O Matthew has a well deserved reputation as an innovator in each business brings unique product strength to customers.
We are excited by the potential for growth from cross Pollinating, the 2 sets of products and market channels.
We expect other benefits from the combination that Brady will discuss in a moment.
We're forecasting this business to generate about $150 million of 2022 revenue in its first full year under our ownership.
As we scale the business and realized high margin revenue and supply chain synergies margins are projected to start in the low double digits and improve to segment averages.
We funded the acquisition with Colfax shares to the Mathis owners, who yesterday launched a secondary offering of the shares they received in the deal.
The offering price last night and the allocation include included a terrific new long term investor who is excited about the potential of both <unk> and our med tech businesses.
The acquisition closed last night, So let me officially welcome the math is team.
I got to spend time.
With key leaders of math as a few weeks ago and was incredibly impressed by the talent passion and dedication IMAX.
I am excited about the future that will create together.
Brady will now take you through more of the acquisition details starting on slide 8 and then Chris will review, our Q2 results and improved outlook.
Thanks, Matt Good morning, everyone on special welcome to our new math its team members.
I'm really excited to be here today and to have the opportunity to speak specifically about our acquisition of masses.
<unk> is a company that I've known and respected for a long time and I've always thought it would be a great fit with <unk>.
There are a number of opt.
<unk> with the combination but in broad strokes are 3 that really stand out. The simple 1 is geographic as you know our retail business is almost entirely in the U S and their business is outside the U S. Therefore, they're significant cross selling opportunities with virtually no commercial disruption on the combination which is unique.
As you know our recon business has historically been anchored to big technologies, 1 day alternate reverse shoulder and 2 the empower 3 D. Mascis on the other hand is really strong and anatomic shoulder and particularly stimulus shoulders and hips led by D. R. M Cup, so expanding each bag with the strength from the others.
Other coal and should elevate the performance of both <unk>.
Finally, both companies are passionate about driving innovation to improve patient outcomes.
In fact, our missions are remarkably similar DJ whose mission is power and motion.
<unk>.
Mission is preservation of emotion.
I was there a couple of weeks ago.
All 3 of these are not only recognize from our perspective, but also about the broader math. This team there is great excitement on both sides of the pond.
But this has had a long and successful history in medical technology that focuses on the development manufacturing and distribution of products and technology for total joint replacements.
As I mentioned earlier, the recount portfolio is very complementary to ours with many differentiated and clinically proven products.
Couple of products I would highlight or that have been finished short stem anatomic shoulder, which in the U S would be called stimulus Mathis with it finished as a leader in the European market.
And as consistent growth in Europe and Asia.
With the platform.
It also provides a terrific access for a reverse platform the shoulder surgeons outside the U S.
The other highlight I'd point to the <unk> Acetabular Cup for total hip replacement.
<unk> has broad acceptance across the EU based on excellent long term clinical success and it's reliable.
To repeat ability across the various patient segments and hip arthroplasty.
As I mentioned earlier. This is 1 of the unique technologies that will expand our range of current offerings in the U S.
Another technology to highlight is that math. This is 1 of the few manufacturers of ceramic components for each orthopedic implants, where they have a low.
Long and extensive clinical history.
Strategically, we see great benefit from having this in house knowledge and capability, giving us the potential to incorporate it into future product innovations across the anatomies.
Like I mentioned at the start geographically map is a great fit all of their sales are outside of the U S.
Historically, the majority of their sales were within Europe, where they have strong share positions in their home country of Switzerland, and solid share throughout we were also impressed with their progress and extremities and broader joint Recon in Asia Pacific, particularly that growth in Australia and Japan.
We also see an excellent opportunity to leverage their international sales channel.
To expand our recently acquired foot and ankle base outside the U S as well.
On slide 9 let's talk about why this makes sense and my math as D. G O together will strengthen our positions.
The acquisition creates a global platform it basically doubles, our addressable market in both extremities into broader joint reconstruction.
Construction market.
No we've had sustained double digit growth in recon for a number of years and with the combination of strength plus utilizing the channel across recon, we see a great opportunity to grow double digits globally across this expanded market.
The shoulder growth dynamics around the world are similar to the U S high.
Single digit growth would reverse expanding more rapidly than anatomic, we feel very strongly that we can accelerate mattresses growth by introducing our market leading alternate reverse shoulder into their channel.
And the broader joint reconstruction market hip and knee.
Tower 3 day knee will strengthen the competitiveness of the math this offering.
The modern knee backed by strong clinical data simply said with the combination of our technologies, we see strong revenue synergies.
Worth, noting the 2 strategic product platforms I've mentioned, the alternate reverse in their power 3 day need products already have CE Mark approval, so our impact opportunity is positioned.
We are seeing.
Beyond growth, we see significant margin opportunities as well, we expect to create savings from increased scale and operational synergies.
Well as a favorable mix shift over time.
From extremities expansion reverse shoulder and foot and ankle as well as accelerating growth in key geographies.
Overall.
To start he felt a winning combination.
It was a critical step in building our recon business.
Moving to slide 10.
The addition of math as we now have pro forma annual revenue of over 500 million of recon.
And a clear path to grow 1 billion in the next 5 years.
We are confident that our proven surgical off.
Offense. It deliberate that has delivered 5 plus years of strong double digit growth will continue to deliver as we go forward, we extended our high growth extremities core into the fast growing foot and ankle segment and now with a massive acquisition, we have doubled the addressable market to drive our clinically superior technologies into globally. Additionally.
Additionally, we have a very.
Overall with the funnel of recon bolt on acquisition opportunities that could get us to the 1 billion Mark even faster.
Our platform has been built on our strategic imperative delivering superior clinical outcomes, which has served us and more importantly, the patients we serve very well.
We believe clinical outcomes are both a key responsibility for us.
Free helped also the key to deliver sustainable growth over time in our Med Tech business. If you will.
Recall, our comments at our Investor day back in March we talked about our vision of expanding to approximately 2 billion in the near term and $3 billion in the longer term scaling on our recon business is a key component in that vision, along with extending our.
Leadership in PNR and expanding into new high growth segment.
Lots of work remains but with our amazing global team made even better with math its strong momentum iconic brands and great customers. We are confident that we will realize that vision.
Let me turn it over to Chris Chris.
Thank you.
Brady I'll start on slide 11.
We had a terrific second quarter.
Revenue levels continued to recover as we've been expecting the med tech businesses solidly growing past 2019 levels, including the recon platform at 10% on a daily rate basis.
He saw.
So grew off 2019 results, including the successful pass through of inflation in the form of price to customers.
Both businesses have a line of sight to further growth improvements in the second half of this year.
Operating leverage and benefits from restructuring projects are flowing through to both the EBITDA and.
EPS lines.
We are successfully managing both significant inflationary pressures and supply chain friction in our businesses.
Q2 operating performance was better than we expected and we were pleased to outperform in the quarter and achieved 56 of EPS.
We also.
Also produced a healthy level of free cash flow in the second quarter the.
The standard work that we strengthened during COVID-19 is driving better sustainable performance across our businesses.
We are carefully managing pressures on working capital that are coming from supply chain disruptions to ensure that we support our growth with financial discipline.
Med Tech business details are on slide 12.
Late last year, we projected that our med tech business would return to growth over 2019 levels by the first half of 2021.
Our business grew 3% over 2019 on a sales per day basis in the second quarter as Covid.
At restrictions continue to become less of a drag on patient demand.
As you unpack. This you can see that the reconstructive part of the business returned to double digit growth. Despite some regions of the U S continuing to have sporadic restrictions.
This growth is impressive given that the industry.
New store operate a bit below pre COVID-19 levels.
The prevention and recovery product lines also grew over 2019, and we expect these growth rates to pick up as countries outside the U S. Further eased restrictions.
Margins sequentially improved as expected on higher revenues and we.
Continue to expect additional improvement in the year related to typical seasonal strengthening of revenues.
Our operating teams are doing a terrific job working through global supply chain constraints to keep up with improved customer demand.
We remain on track to deliver a healthy step up in EBITDA margins as outlined.
At our March Investor Day, and we expect to continue to manage logistical and supplier challenges through the end of the year.
Turning to slide 13, our fab tech businesses successfully managing the significant wave of raw material cost inflation by using dynamic customer pricing actions.
<unk>.
These inflationary pressures are not abating and we're projecting another 4 points of price in the second half to reflect customer pricing actions already taken.
Isolating for the pricing actions the businesses underlying volume growth came very close to matching 2019 levels in.
Sir.
The developing economies of the world remain constructive and growing in European and North American customer demand is getting healthier.
Overall, we expect volumes to continue to strengthen and we're projecting volume growth versus 2019 in the second half of this year.
While the fixed on the show as a record EBITDA margins of over 16%, which Matt covered off earlier in detail.
This equates to 18% EBITDA margins, so I want to say congrats again to shop on the team who are well on their way to the 20% EBITDA margin objective outlined at Investor day.
On the court.
Our updated outlook for the year is included on slide 14.
Based on strong second quarter performance, we are again, improving our guidance for the year, we are expecting $2.10 to $2.20 per year of adjusted EPS up 5 from previous guidance.
Since this now includes $3 <unk> of net dilution from the math this acquisition in the second half of this year.
We continue to expect the typical seasonal pattern of revenue and profit and are forecasting third quarter earnings per share of <unk> 50 to 55.
We're also.
We're projecting at least $25 million more free cash flow of the year and have increased our full year guidance to $275 million or more.
We continue to track to about 90% conversion in the year before any outlays related to the separation.
As noted earlier book.
It does have strengthening revenue pictures in our slide highlights some of the key components.
In addition to healthy organic growth in both businesses, our acquisitions are off to a great start.
As noted earlier business margin performance is forecasted to be in line with the amounts communicated at Investor day.
Business the tax rate is expected to remain in the low twenties in the second half of this year in interest cost should be sequentially lower based on the $700 million bond redemptions that occurred in April.
On Capex levels are expected to remain in line with amounts originally communicated.
We will wrap up our prepared.
Paired remarks on slide 15.
We entered 2021 with significant growth planned for revenue profit and cash flow.
The first half of the year has played out even better and for the second quarter in a row, we have improved our annual guidance.
We have been actively expanding our med.
Business with acquisitions that helped to position it for sustainable improvements in growth.
Matt. This is just the latest example, and we're excited about the growth and margin synergies that this acquisition creates for our fast growing <unk> platform.
Yes.
Our strong operating performance demonstrates that our businesses are well.
<unk> to be separate independent public companies.
We're making great progress on this strategic project and continue to target completion in the first quarter of next year.
And with that I'll ask the operator to open up the call for questions.
Thank you so much.
Position, we will now begin the question and answer session. As a reminder, if you wish to ask a question. Please press star 1 on your telephone.
On your telephone keypad MLB Ross depends on their request you may pressure Ross.
Yes.
We'll pause for just a moment to compile the Q&A roster.
First question from Scott Davis from Melius Research your line is open.
Hey, Good morning, guys, Hey, Scott Chris Mike.
Good morning.
Well you guys have been busy.
Matt This looks interesting too.
On the masses.
Is it more exciting from a channel perspective or product perspective kind of if you could just talk through that if Randy wants to take that or Mad whichever is fine by me.
Barry go ahead.
Yeah.
To me I would say, it's actually a blend of both I think.
So great question you know is on.
I mentioned.
What are where their strengths are.
They're those are opportunities for us and so some of their hip technologies are very specifically like I said, the arm Cup, which is quite unique hats.
Non <unk> data, we view that technology as it is a big.
Big opportunity in the U S as.
<unk>.
Quite frankly, some of some of the really unique aspects from a furnace on a.
Short short stem and stimulus shoulder.
But that channel is something as you know that we really need it and so when you when you look at our particularly our alternate reverse.
Having an opportunity to really put that technology that is just really changed the shoulder environment in the U S into a great channel a great direct channel was it you know a humongous part of the strategy.
But then as I said there they're knee also has been really lagging behind the rest of their growth.
And I can tell you that when I was over there a couple of weeks ago. Their teams could not be more excited about both our reverse shoulder and the priority. So it's a blend of both for sure.
Brady do you have to go through any regulatory or any kind of channels to get your reverse shoulder into that market.
I know theres, a lot of different health care systems over there, but so perhaps it's country by country, but maybe you could help us navigate that a little bit yeah. So you know as I said earlier as you look at Europe, we already we have the CE mark on our alternate reverse and so.
There's not really things.
For us navigate on on the on the main product line that the lead product in our in our reverse platform now there are other new reverse components that better when I say, new or there are there additional reverse components that that are not you know that main piece that we've launched over the last couple of years and so we will have to go.
We're you know we're in process on those and had been in process, even before acquiring masses.
So our main alternate reverse CE mark.
So it'll make a.
Big opportunity for impact early in Europe, and then as we you know and some of the other countries like Australia and Japan.
Additional steps on top of the C E.
But early on we should be able to really really go quickly with our main reverse platform.
Okay, and so I, usually don't ask more than 2 questions, but I'm dying to find out how.
Matt how how long do you have your on time deliveries gotten.
In this environment or have you been able to keep the wheels on getting product on time or is it really off yeah, well like I mean like everybody else.
I think we've definitely had a lot of pressure on the supply chain in both businesses and I think the teams have been doing it a fabulous fabulous job I think philosophically, we we put the customer.
Customer first and I think both businesses have been doing on doing a great job of serving customers in having.
Customers are satisfied as possible and having most of what doesn't get served go into backlog versus go go to somewhere else.
And so I'm really proud of what the teams have been.
To do there I think the teams have done a nice job with some of the planning to try to make sure that we're as positioned as possible for some of what we're going through but there is no question that we built up built up some backlogs in each of the businesses and we've also had some some frictional cost in the businesses and.
<unk> business and so we're looking forward to in the coming months and quarters, some easing of that situation and being able to pull down some of that backlog and leave some of those short term costs behind.
Okay. Good luck congrats guys. Thank you. Thank you.
Thank you so.
So much next question from.
Alright, Joe Giordano from Cowen.
Please go ahead.
Hey, guys good morning.
Hey, Joe Hey.
Just curious when you bring these types of products.
To Europe.
Do you already.
In particular, the surgeon network on like a new product like reverse I know I know the vs used in Europe, but do you have the right kind of.
Channel of surgeons to promote that product already existing in Europe or is that something you have to kind of go get.
Oh.
Good morning, Jos Brady, what I would say is.
Have the surgeons that are doing anatomic shoulder for matters and their key key Kols are also the same surgeons that would.
Be doing reverse shoulders as well within their practice and reverse is really expanding.
What.
It was interesting.
Something that.
We learned through the process was.
If you look at their shoulder development pipeline with their R&D team.
Outside of the acquisition there.
They are key focus was developed to develop a more lateral lives reverse similar to ours and that's from their kols.
We believe the channel is ready as well as their surgeons.
Okay.
To really take that roam within in our our shoulder surgeons that.
It helped us on that development.
I have deep relationships also.
Broadly outside the U S and so I think it'll be a great blend between the 2 sides and this product will really help to accelerate.
Or read a strategy day, you had in place that they've been growing their shoulder really fast and just really needed the right reverse so.
We're well positioned.
Got it and then on on Aesop.
Can you maybe just talk to how that look geographically and the margins there.
With that kind of price component pretty surprising to be able to pull off margins like that so can you maybe talk about how much more room, there is internally to drive.
On drive the cost side.
Yeah. So first of all the geographic question I think we continue to have.
A similar story to what we've been talking about that.
The emerging market parts and high growth market parts of the business that make up over over half of the business are having.
Solid growth this year on top of solid growth next year or so so a nice 2 year run of growth and the developed markets keep improving and I've not gone back.
Back to growth over 19, but certainly have strong growth over over 'twenty and so theres still room to go there.
On the volume front than in developed markets.
And so I think we've been certainly happy with what's happened so far in that business with most markets moving moving forward quarter by quarter on the margin front yet.
And he's done a terrific job and as I talked about it's been a it's been a 5 year journey and I think it is important to note that some of the key things that have fueled the aesop journey over time, our tools that we're actively applying on the DJ on front end getting increasing levels of momentum to make sure that we can fuel that journey to 25%.
The team that we talked about it at Investor day and to certainly the team has done a great job on aesop of continuing to push.
Pushed the price through to cover costs and keep driving productivity.
And so were we.
<unk>.
Certainly signaled there with the guidance that that the margins will be up nicely over 19.
EBITDA and we also see the team having a very clear path to that 18% EBITDA margins.
The 20% EBITDA margins that were shared at Investor day.
Thanks, guys.
Thank you so much.
Question from.
Chris Snyder from UBS Your line is open.
Thank you guys. So first question on math is on the international opportunity.
Of the existing.
Roughly 303 hundred $50 million of reconstructive revenues.
How much of those.
<unk>.
Is there an opportunity in the international market for all of that just a sub segment of that.
And then in that same vein.
Can you maybe talk about any incremental challenges of integrating mascis relative to the previous string of bolt ons you guys have done because.
This 1 is I guess, 1 substantially larger than obviously, a very different from a geographic perspective.
Yeah, I'll make a quick comment there and then let Brady provide some some additional.
The color there.
Again I think.
As Brady has talked about there is a lot.
On a opportunity across the full.
Product line that we've got and maybe you can provide some more color on how much supplies into the international markets.
But as far as.
The acquisition again, 1 of the great things about the acquisition is how complementary it is.
And that there is kind of a limited situation almost no channel their product overlap.
Which.
Those things can be very difficult to work through particularly in the orthopedic industry and so the fact that there is so little channel or product overlap is just terrific and I think paves the way for that.
Healthy acceleration of growth quickly as the cross selling synergies.
Come through.
We've set.
It's a business up thoughtfully in terms of having the right amount of autonomy.
To be able to execute in those markets, but then also.
Having opt.
Opportunities to drive leverage in the supply chain and leverage and product innovation and so there's been a lot of work actually.
With.
A number of us Brady and I and others really thinking through how do we havent really set this thing up for success structurally on that right balance of agility and scale on it I think we've got a great game plan and are off to a great start Brady on private a little more color there.
Well said.
Mike.
I would tell you to.
And technologies and products and so from a from a product perspective, we outlined a couple of those that are critical but.
For instance, I mentioned the strength of their hip portfolio, which is really good and we've had fantastic growth overtime and also very much on recent years.
You think about.
Some of the technology.
But we have in the U S that we've had and we can grow over the U S are quite similar or fit until stem that well.
Well suited.
On both continents and in place however.
In the hip for instance, 1 of the things that we've launched recently, which is our dual mobility.
Big opportunity for that business on a revision stem for hip another big opportunity. So.
I really think in each of our key segments, starting with the upper extremity with shoulder not just reverse some other platforms. There are 2 there are products that will go both directions.
And really help both businesses. So I think I think the majority of that 300 plus million that you mentioned.
Really applicable on both side. The other thing I would tell you is that on the technology side, which is 1 of the things that we saw as a big opportunity. There are some key technologies that are in on the U S.
S side have been solely focused on the U S like our P square.
Force coding.
And like they are investments that you've heard us make an exercise we view those as big global opportunities that we can take across all the channels and at the same time the RM technology.
That has been lost within the hip that also we think is applicable across other anatomies. We think will play extremely well in the U S. Market also so I you know I think the majority will fit very well.
I appreciate all that and then I wanted to follow up on <unk>.
SAP actually yeah. So over the last couple of years. The majority of Colfax capital has been directed towards Med Tech M. But so can you talk a little bit about the opportunity for a standalone E. SAP you know the business will have $450 million.
Or so of EBITDA.
You know to really reinvest you know you guys have talked a lot about higher growth verticals. You know there is that where we should expect all the capital are there any regions I know, it's a very diverse but are there any regions you think.
You know you could try to push into and lastly are there opportunities to invest to drive further efficiency in the business.
And get these margins on you know continuing to go higher.
Yes, so a couple of different different thoughts on on that the first is that youre correct that in the past couple of years as we signaled the day, we acquired D. J L. We have.
Invested most of our acquisition capital in the Med Tech.
Tech business and have made terrific progress in shaping and expanding that business in a very positive direction. If you step back and look more at the past 6 or 7 years, we've put a lot of important capital into the <unk> business as well that is really bearing fruit today and a number of strategic acquisitions that were made over time.
They were terrific we executed.
And the most recent significantly on what with the GCE acquisition that is performing tremendously well strong growth last year and this year. So now.
2 years of strong growth really powered right through.
Some of the challenges of last year and substantial expansion in.
On the margins of that business and it opens up all kinds of additional avenues as to where we can go in that gas control space and so there has been quite a bit of.
Capital deployed by the team in Aesop book through the years in a very productive way and Thats part of what made it such a successful business today alongside of all the great operating improvements.
In the business looking forward in the business I've already talked about on the margin front. There is currently headroom to to continue I think <unk> shared some of this at Investor day. Some of the same things that we've been driving for years in the business in terms of productivity supply chain restructuring and simplification and some of the back office.
Simplification and automation.
Those still have room and the acquisitions, we've done the most recently have higher gross margins and create paths tire margins. So we do see continuing opportunity to move forward some incremental investments in restructuring that will help keep lifting the lid, but also just.
Operational improvements and high margin growth that will help to keep driving the margins up to that 20% EBITDA and beyond that was shared at <unk>.
At Investor Day in terms of the acquisition pipeline.
We have a healthy set of opportunities.
Within within the Aesop business there are there continue to be.
Point, while any given region is pretty concentrated in that business and how does that has some some real benefits. It's still a pretty fact fragmented global business with the leaders at the 3 leaders in the business, having maybe 35% share of the global market and so.
So there is still plenty of opportunities to pick up regional assets that.
And high growth.
Countries there are still.
Attractive product line additions like like the Tbi torches edition that we did a number of years ago that gave us additional technology and exposure for robotics or those kinds of opportunities there are additional.
Technology based opportunities digital opportunities.
<unk> like some of the software acquisitions that we've done.
And there are some straight on product bolt on opportunities and the teams got a clear view as Sean shared that the acquisitions are going to be focused on enhancing our growth and continuing to bring down the cyclicality of the growth enhancing our margin profile and opening addition.
<unk> space and then finally, the <unk> business does have attractive attractive adjacencies again I think.
<unk> is a great example, and theres more to do in that.
That space and there are other logical directions that the business can go with.
With adjacencies that enhance the growth profile strength.
And the margins and open up additional marketplace to address organically and address through other acquisitions and we feel as I said in the comments that the 2 and a half the board put a lot of thought into this and feel that the 2.5 to 3 times capital structure.
Debt that we've indicated as what we expect for <unk>.
<unk> as an independent company, if you put that alongside of the strong and consistent cash flow that the business has had and the demonstrated operational execution capability, we feel like that creates.
Healthy and value the envelope to execute on the growth strategy that <unk> outlined at Investor day.
And growth to grow the business nicely in the years to come and expand the business in the years to come.
Thank you for all that.
Mhm.
Thank you very much next question from Jeff Hammond.
Good morning, guys, Keybanc, Hey, Jeff Good morning, gentlemen.
Just on the deal can you just kind of talk through the rationale for doing equity it seems like the sellers wanted cash.
Did your recent equity offering I don't know if that speaks to the pipeline behind it but it seems like that capital is cheap and the balance sheets already in much better shape.
Yes, Jeff Thanks for the question Yeah, a few things first I think.
I hope you get a sense from the discussion here on the call and from the things like Brady share.
<unk> is a terrific acquisition, it's highly strategic really really strengthens our med tech platform and opens up a great avenues for growth and there is a lot of synergy.
And this acquisition really over $15 million in supply chain synergy opportunities.
Annually by the time, we get about 3 years in so there's a lot of synergy here and so this is just a great deal for our investors first and foremost.
Second we've consistently said that we're going to we're going to set both these businesses up for success.
And define that as aesop.
<unk> healthy room to execute its strategy and we've painted in on this call. The 2.5 to 3 times leverage that we think does that and we've also said we want to make sure that med Tech has a clear path to grow to $2 billion plus quickly and be high growth.
Med Tech innovator and we feel like.
The equity financing helps to create the right envelope for those commitments that we've made around these these 2 companies.
And finally, we've consistently said that we expect this to be a tax free separation and this transaction in the form of it.
As part of part of how we are executing that tax free separation.
Okay, Great and then just.
Just on the margin dynamics of Med Tech.
Is there anything unique in some of the supply chain challenges, they're seeing vs aesop, which seems to be kind of overcoming.
Maybe at least in the margin drop through a little bit better.
Yes, Jeff So theres a couple of things 1 is certainly the sharpness of the drop in recovery Med Tech last year was more severe and I think that put more stress on on the supply chains and so it's the supply situation.
Those minutes, probably a little bit more little bit more aggravated in.
In that business.
And the kind of.
Customer expectations, and what you need to do to protect customers in the business.
I think a little bit higher and that has resulted in more expediting costs, both in terms of bringing stuff inbound.
<unk> and stuff outbound and and more kind of extra cost in the factories from just kind of doing doing whatever it takes so I think there are some differences there and then there is also there is some.
Inflation coming through both of the businesses a lot any side with all the steel as well as other things, but also inflation coming through the med Tech business.
And he.
<unk> I think with the steel inflation already coming through the pass through efforts around the broader set of Inflations.
Theyre not theyre not easy, but the team has kind of in the industry has a kind of a well worn path of.
Of that going through the industry.
And the Med Tech industry is there is some some inflation.
<unk> been through I think it's going to take.
A little bit more time and specific effort in different areas to step by step get that inflation pass through an industry that operates in a little different way.
Okay and then just last 1 you mentioned I think supply chain is a cost opportunity, but just talk more broadly.
<unk> come about.
The mattress business from.
Low double digit margins too.
The corporate average.
Yes, So let me jump in there.
So first from a supply chain standpoint, they are big opportunities, we've got the opportunity to optimize across across the supply.
Broadly optimize what's made where opportunity to in source.
<unk> each each of our businesses have a meaningful amount of outsourced product into that into that implants.
Supply chain and we've got a chance to to in source more and more over time, we've also got productivity.
The opportunities.
Change in terms of automation technologies and different efficiencies in some cases.
Investments net of that will drive those in some cases cross sharing of capabilities.
That will drive those and so we see that significant supply.
Supply chain impact that I talked about and certainly.
<unk> biggest opportunity to drive up the gross margins and ultimately the net margins of the of the business. But then also again opportunity to scale the business over time as I said, we've got on integrating structure that is going to preserve that agility of each of our businesses, but at the same time drive scale on the dimensions.
That makes sense.
In the short term will be focused on making sure that we're getting after all of the growth, but then as that growth comes through in the coming years there'll be scaling of that of that infrastructure that will also help with the margins and then third Brady talked about it our revenue synergy plans are disproportionately weighted towards.
Towards higher margin products, and that's things like shoulder out of the gate. That's also certain countries out of the gate that have higher margin profiles and then over time as the foot and ankle products can come through they will also contribute.
Higher margins and so we will get a mix effect that comes through as well.
Combination of those we feel very comfortably youll get the business at least.
To fleet margin averages and certainly opportunity to go beyond that over time.
Okay. Thanks for color.
<unk>.
Thank you. So much next question from Andrew <unk> from Bank of America. Your line is open.
Thanks. Good morning. This is David Ridley Lane on for Andrew.
Question on Fab Tech.
Volume growth implied in the second half it looks like sort of low to mid single digits.
So first is that math correct and then.
<unk>.
What are you seeing.
Seen that makes you a little bit more conservative.
On the volume growth.
In fab Tech in the second half of the year.
Yes, So I think Chris talked about the fact that we're about passing through the volumes of 19 here in the second quarter and that we expect to have continued improvement as.
As we move into the back half of the year.
So, yes, so I think that would.
Matched about with your comments, although they'll continue to be price coming through the business as well and so.
There's a there's a kind of a balance there.
And I think certainly there is a good.
With a healthy recovery.
Underway, but at the same time, we're just cognizant of.
Around the world some of the different places that are that are still having some significant challenges around COVID-19 and we're trying to make sure that we've got a.
The appropriate view of how things are going to make their way through this year and into.
Into next year.
Versus an overly aggressive view and I will tell you that from a planning standpoint.
We've tried to make sure on each of the businesses.
That we think about what the possibilities are for how the recovery could shape as well as what our forecast is and we're trying to make sure.
Our supply chain.
Gaining his thoughtful up against that and that where appropriate we.
We planned for a little extra inventory in case, we get a little stronger recovery.
And make sure that we're ready to be able to serve that and so I think we're trying to just walk through this step by step the team has done a terrific job and we're making progress.
<unk> plan.
Got it.
And then on unmet tech.
If I take the 59% organic growth and the $14.2 organic EBITDA margin I get about 35% incremental incremental margin.
How much of.
Every contact where the supply chain issues in the quarter on a year over year basis.
If it wasn't for those supply chains.
Issues, what do you think your organic incremental margin would have otherwise been.
Yes, sure I'll tell you I'll take that 1 we've made it clear that our priority is to serve.
And then in tumors and patients and to make sure that we can.
Keep the supply chain going for our customers' benefit there and that has that has meant we've had to work a bit harder there is some additional effort in <unk>.
Actions that we've taken and certainly some costs that have been incurred along the way in and that does show up.
Show up.
<unk> and the <unk>.
We've been talking about this I think for a little while now and we would expect is.
As the supply chain in the world sort of corrects itself.
And we get pass that then we get to we get to a healthier spot.
It's weighing on us a little bit here I would say kind of in the sort of low low.
In the single digit billions in.
And perhaps a little bit a little bit more here and there but.
But we are definitely incurring like everybody extra effort here, but in our case to maintain the outperformance relative to peers. So we serve customers. We get the revenue we continue to take share and that really positions us well for.
<unk>.
Not just for this year, but as we continue to progress on.
The only thing I'd add there is you asked about on the on Incrementals, obviously from last year.
Storing of temporary cost measures at a pretty significant factor in the Incrementals and then comparing to 19, there is quite a bit of growth investment and talent investment that we put into the end.
Or the incremental system.
Okay that makes sense. Thank you very much.
Okay.
Thank you. So much next question from Nathan Jones from Stifel. Your line is now open.
Good morning, everyone.
Okay.
So last.
Question, Hey, Brady, we've talked about the opportunity to cross sell various products.
It's weighted Matheson dji.
Can you talk about why it is that Matthew doesn't already have any revenue in the U S did a lot of channels to market or are there any regulatory hurdles that need to be overcome to do that.
Yes.
Good morning.
So great question and what I would just be it's a very simple response on that is.
Really for companies to compete in the U S that they have to build a channel.
And building that channel successfully.
In the U S is difficult.
And in some ways, it's not dissimilar to what our approach has been which is not heavily trying to invest and build on organic channel outside of the U S. So.
Companies had at least in this space.
<unk> made the same decision and so.
Really.
That's it it's just expensive to build a channel and in difficult to compete in.
In the U S market from a regulatory perspective, though the majority of their product I would say the large majority if not all of them.
It should be fine.
K products, which would mean, they're they're not going to require clinical trials as we bring those products across into U S.
So it should be fairly smooth transition to <unk>.
But to sell their products in the U S.
Okay, and then my follow up for Matt.
Matt you talked.
<unk>.
On some products some some business going into backlog rather than going to competitors, which is reasonable everybody's got the same kind of supply chain challenges can you give us some idea of the scale of the amount of revenue that you think is sitting in backlog at the moment that would have otherwise.
<unk> run through the P&L.
On the first half of the year and when you expect that to normalize.
Yeah, Nathan I'm not comfortable given the scale, but I will say that each of the businesses.
We have some excess backlog as we as we clear mid year here and.
Expect break.
Likely most.
Have it run through again.
What's in the backlog now will run through it's just a question on how the order flow comes as the weather.
Whether there is still an elevated backlog as we as we exit the year, but I think it is.
There is some opportunity here.
And.
I think we feel like in both of the businesses, we probably had.
A situation, where we hear from the marketplace that we're doing at least as well if not better than our competitors in terms of serving the marketplace and certainly when we when we look at our growth whether it's year over year were from 19, we feel like across both the platform.
It forms in Q2 and year to date, we feel like we're showing very strong organic growth versus our peers and outperforming even with.
Some.
Some revenue going into backlog.
Fair enough thanks for taking my questions.
Thank you so much next.
And from Joe Ritchie from Goldman Sachs on your line is open.
Hi, This is Turner on for Joe Ritchie and good morning, guys.
Good morning, good morning.
So you all mentioned you're guiding to core EBITDA margins, 20% plus for Med Tech.
Non core EBITDA margins trend.
Question on the Med Tech so far this year.
First half and what's the framework for improvement going forward in 2 weeks.
Yes.
The margin progression in this business is linked to the sort of seasonal revenue progression as well so that you typically see the.
Lower margins in the first quarter and you see the strongest margins in the fourth quarter, that's been a bit of a demonstrated pattern in the business and Thats..1 that we would expect to see continue to play out as you get the operating leverage on the on the higher revenues.
And what I'm sorry, what was your other question.
How it's going to shape out for the second half.
Yes, so we would expect to see the same sort of progression.
For this year.
And so we've given yes.
Our expectation for.
For the total margins for the year.
And on.
On a core basis, we've said, we've broken out the acquisitions as well.
We're well on our way to achieve that step up in margin and as we've talked about we've also got the clear path to 25% on a longer term basis. There as we continue to reshape the portfolio driving faster growth and drive the benefits of CBS and the business just as we've done with.
You've seen us do with Aesop on others.
We feel like over time.
Yes, the only thing I'd assets.
I would just add there we had a big nice step up in core EBITDA margins from Q1 to Q2.
As we talked about even with a little bit of pressure.
Sure.
Q3.
Tends to be.
A little more.
On a seasonally lower than Q.
Q4, and so we expect to have a little bit of improvement in core margin does move from Q3 to Q2 and Q3, and then really significant opportunity in Q4, as we hit the highest revenue quarter as well as when we when.
When we expect to have more of these temporary costs behind us.
Great.
Great that makes a lot of sense.
If I could ask a question about sort of M&A plans I mean looking at your Investor Day, you outlined a few areas new cortisol.
Not yet.
Matt This acquisition you got into sports Medicine could you talk about winter future.
To be more focused on building out that.
You know versus calling internationally.
Specifically also.
The 2019 Investor day.
You gave some points on the portfolio breadth and same surge in sales I'm on.
I'm wondering how that's progressed and how your future sort of.
Our targets for M&A willing to incorporate Hussein.
You know things.
Things.
Yeah, So maybe Brady can come maybe on the same surgeon sales in a SEC, but you know as.
As far as where we're thinking about going with M&A in Med Tech I think we've been consistent with our comments here and talk quite a bit.
About at Investor Day, and I'll reiterate that here, we see quite a bit of opportunity in the existing ortho markets, where we participate today.
Right Great bolt on technology adds that we can do in our in our existing.
Businesses like some of these.
So these great foot and ankle ads, we've done after the first at foot and ankle acquisition like the like your AD that shape PNR into a positive direction.
We see more of those kinds of bolt ons to do in the core markets, where we participate today.
Today.
We also see opportunities in the broader ortho space, but.
We've got a view into that whole space based on how we how we compete in surgical and our PNR business and as we think about where else to move on the orthopedic space will be very focused on things that enhance our growth and margin profile the way that the foot and ankle.
Good.
And then there is.
Logical adjacencies for us to look at as well that are adjacent to where we are in or so and opportunities to move into high growth high margin areas. So a rich pipeline of opportunities that we're going to execute through and certainly a new.
Number of those do create same surgeon growth opportunities.
<unk> you want to talk a little a little bit about.
For example, how the foot and ankle acquisitions as we've put them together have created same surgeon crossover opportunities.
Yes sure.
And you certainly would see that both with what we've done in foot and ankle if you'd take.
If you look across that platform.
Form.
With med shape <unk> trillion for instance trillion has had predominant focus an application on the on the forefoot mid shaping the hind foot and then with the Staples actually both had staples were met shape was certainly had a stronger share.
That plays into the Midfoot it towards the <unk>.
Well, what we're seeing is we're putting those businesses together same surgeons doing procedures, all the way across including ankle total joints.
And so that that cross selling is 1 of the big opportunities New we're early there, but we're very confident in our ability to take share as we go. Additionally.
<unk> as you look into upper extremities and you you you know.
When you think about strategically what we're doing from an M&A perspective, the shoulder arthroplasty, a surgeons that we work with are historically in the U S and today are around the world are going to do about 50.
50 ish percent of their procedures are arthroplasty and the balance of those are our sports medicine and trauma in the shoulder those same surgeons and so there are a number of opportunities as we expand our business and technology within the same group of surgeons in AR.
Same store sales you.
With deep customers with long term trusted relationships with with us.
Yeah.
Yeah.
Great. Thanks for the coming on.
Okay.
Thank you so much that is all the time, we have at the day for questions Mike legal.
Go ahead.
Thanks, everyone for joining our call day, and we'll talk with you soon thank you.
That does conclude our conference for today. Thank you for participating you may all disconnect.